Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment

Abstract

Many cancers have evolved various mechanisms to evade immunological surveillance, such as the inhibitory immune checkpoint of the CD47-SIRPα signaling pathway. By targeting this signaling pathway, researchers have developed diverse nanovehicles with different loaded drugs and modifications in anticancer treatment. In this review, we present a brief overview of CD47-SIRPα interaction and nanomedicine. Then, we delve into recent applications of the CD47-SIRPα interaction as a target for nanomedicine-based antitumor treatment and its combination with other targeting pathway drugs and/or therapeutic approaches.

Introduction

The CD47-SIRPα signaling axis plays an important role in antitumor immunology, tissue homeostasis and remodeling (Logtenberg et al., 2020). Upregulated expression of CD47 on tumor cells increases the interaction with SIRPα on the myeloid cell membrane, leading to a release of the “don’t eat me” signal to evade the phagocytosis of myeloid cells, which is one of the primary mechanisms of cancer and disease formulation (Oldenborg et al., 2000; Jaiswal et al., 2009; Willingham et al., 2012; Hayat et al., 2020; Logtenberg et al., 2020). Hence, increasing studies have focused on the CD47-SIRPα interaction to achieve better therapeutic efficacy for cancer and other diseases (Ho et al., 2015; Petrova et al., 2017; Yanagita et al., 2017). Nevertheless, similar to other conventional medical treatments, the disadvantages of systemic administration of CD47-SIRPα blockade, such as nontargeting distribution, side effects, and short half-life period, have limited its translation to clinical use. These disadvantages can be abated by nanotechnology, which also offers nanotemedicine a promising opportunity to develop. In this review, we will discuss the recent achievements of CD47-SIRPα interaction-based antitumor nanomedicine from the following three aspects: CD47-SIRPα interaction, an overview of nanomedicine, and the role of the CD47-SIRPα checkpoint in nanomedicine-based anticancer treatment.

Overview of the CD47-SIRPα Checkpoint

CD47 Structure

The CD47 protein, a member of the membrane protein IG superfamily, is ubiquitously expressed on varieties of types of cellular membranes, especially on senile erythrocytes and cancer cells (Hayat et al., 2020). Its molecular structure includes a single IgV-like extracellular domain at the N terminus, a highly hydrophobic stretch with five membrane-spanning sections and an alternative splicing cytoplasmic domain at its C terminus (Brown and Frazier, 2001; Mushegian, 2002). By interacting with integrin and TSP-1, CD47 is involved in a variety of physiological processes, such as migration, adhesion, proliferation, differentiation (Lindberg et al., 1996; Liu et al., 2001; Lymn et al., 2002). As an inhibitory receptor, CD47 can bind with SIRPα to not only inhibit phagocytosis by phagocytes but also inhibit the activation and maturation of dendritic cells (DCs) (Oldenborg et al., 2000; Latour et al., 2001; Lutz and Bogdanova, 2013). In addition, CD47-SIRPα also regulates neuron development and bone remodeling (Barclay, 2009; Maile et al., 2011).

SIRPα Structure

SIRPα, a member of the Ig superfamily (IgSF), consists of three Ig-like extracellular domains at its N terminus four tyrosine phosphorylation sites and two immunoreceptor tyrosine inhibitory motifs (ITIMs) in its cytoplasmic domain (Adams et al., 1998; Hayat et al., 2020). In contrast to the ubiquitous expression of CD47, SIRPα is limitedly expressed on macrophages, monocytes, granulocytes and neurons (Adams et al., 1998).

CD47-SIRPα Interaction

The N-terminal Ig-like extracellular domain of SIRPα binds with the N-terminal IgV-like extracellular domain of CD47, resulting in the phosphorylation of ITIM of SIRPα and recruitment and activation of protein tyrosine phosphatases, especially Src homology 2 including SHP-1 and SHP-2, dephosphorylation of the downstream molecule ITAM, the accumulation of myosin IIA damage in the phagocytic synapse, releasing the “don’t eat me” signal, leading to an inhibition of phagocytosis (Hayat et al., 2020; Logtenberg et al., 2020; Figure 1).

FIGURE 1

Homeostasis of cells and tissues depends on a balance of regulation of pro-phagocytic signals [calreticulin (CRT)-low density lipoprotein-receptor related protein-1 (LRP-1), Fcγ, complement receptor] and anti-phagocytic signals (CD47-SIRPα) (Oldenborg et al., 2001; Chao et al., 2010a). Chao et al. demonstrated that CRT plays a leading role in pro-phagocytic signals and is essential for anti-CD47 antibody therapy in multiple human cancers. In their study, the in vitro phagocytosis assays were performed by incubating primary human normal cells and cancer cells with human macrophages with a therapeutic dosage of anti-CD47 antibody, and showed that primary cancer cells were obviously phagocytized, whereas no phagocytosis of normal cells was observed, suggesting that blocking the CD47-SIRPα is not the only rationale for pro-phagocytosis (Chao et al., 2010a). Note that the anti-CD47 antibody with intact Fcγ should be utilized with caution given the pro-phagocytosis role of Fcγ, which could increase systemic toxicity by enhancing antigen sink effects (Ingram et al., 2017).

Increasing studies have concluded that the antitumor effect mediated by blocking the CD47-SIRPα interaction mainly owes to the activation of innate immune responses [including phagocytosis by macrophages and the antibody dependent cellular cytotoxicity (ADCC) by neutrophil granulocytes] (Jaiswal et al., 2009). However, it is important to note that the results of these works were based on xenograft models, which may favor innate immune responses to kill tumor cells with some unique features (Majeti et al., 2009; Chao et al., 2010b; Willingham et al., 2012). Liu et al. used syngeneic immune-competent mouse models to exclude these effects (Liu et al., 2015a). In this study, the mouse anti-CD47 antibody showed an evident antitumor effect, especially by intratumoral delivery, and the therapeutic effect was diminished when CD8⁺ T cells were depleted. In addition, CD47-SIRPα blockade activates the maturation of DCs and boosts DC-mediated antigen cross-presentation and cytotoxic T lymphocyte induction. Hence, the CD47-SIRPα signaling axis is an inhibitory checkpoint that bridges innate and adaptive immunity for tumor evasion.

Strategies for Inhibiting the CD47-SIRPα Interaction

According to the different signaling pathway blocking sites, the strategies for inhibiting the CD47-SIRPα interaction can be divided into three types: molecules that inhibit the CD47 protein on the tumor cells, molecules that inhibit SIRPα protein on the myeloid cells, and inhibitors of the glutaminyl-peptide cyclotransferase-like (QPCTL) enzyme, which is necessary for the maturation of CD47 protein (Logtenberg et al., 2020).

The strategy targeting CD47 on tumor cells has been the most commonly studied. For instance, Hu5F9-G4, a humanized anti-CD47 antibody with a human immunoglobulin G4, has been proved a potent antitumor effect in preclinical experiments and clinical trials. In a malignant pediatric brain tumor-bearing mouse model, administration of Hu5F9 evidently inhibited tumor growth and showed significant survival benefit (Gholamin et al., 2017). However, CD47 is not only over-expressed on cancer cells, but also expressed on normal cells, such as ethrocytes. Therefore, administration of CD47 blocking agents would lead to anemia and “antigen sink” effect. In the development of CD47 targeting agents, multiple approaches have been employed to solve these problems, such as change in the mode of administration (Liu et al., 2015b; Advani et al., 2018; Sikic et al., 2019); dual targeting bispecific antibodies of CD47 (Dheilly et al., 2017; Shi et al., 2020; Wang et al., 2021); CD47 antibodies/SIRPα fusion proteins (Petrova et al., 2017; Meng et al., 2019; Puro et al., 2020; Andrejeva et al., 2021). From the efficacy of view, dual targeting bispecific antibodies are more promising. Wang et al. designed a CD47-PD-L1 bi-specific antibody, named IB322 (Wang et al., 2021). As a dual inhibitor of innate and adaptive immune checkpoint, IB322 efficiently triggered the tumor cell phagocytosis by macrophages and killing effect by T cells and induced complete tumor regression in vivo. Moreover, IB322 showed negligible RBCs depletion and was well tolerated in non-human primates.

Compared with the wide expression of CD47, SIRPα is restrictedly expressed on myeloid cells and neurons (Adams et al., 1998). Hence, biologicals that target SIRPα do not suffer from amenia and “antigen sink” issues (Yanagita et al., 2017; Voets et al., 2019). For example, Ho et al. developed an engineered, high-affinity, CD47 variant (termed Vecro-CD47), which could remarkably increase the affinity to wild-type (WT) SIRPα and disrupt the CD47-SIRPα interaction, thereby promoting macrophage phagocytosis of tumor cells (Ho et al., 2015). Voets et al. developed a humanized mAb ADU-1805, which inhibits the CD47-SIRPα signaling pathway by closely binding with SIRPα, showing similar antitumor efficacy as the anti-CD47 antibody with good safety in vitro and in vivo (Voets et al., 2019). However, researches and clinical trials focused on SIRPα blocking target are fewer than that on CD47 blocking target.

Inhibitors of QPCTL enzyme is another promising strategy that does not result in anemia easily and “antigen sink” issues (Ingram et al., 2017). Logtenberg et al. reported that both genetically and pharmacologically blocking QPCTL activity enhanced antibody-dependent cellular phagocytosis (ADCP) and ADCC of tumor cells (Logtenberg et al., 2019). Moreover, the intervention of QPCTL activity can alter the immunosuppressive tumor microenvironment (monocyte skewed, myCAF, TGF-β) to a proinflammatory (macrophage skewed, iCAF, IFN) milieu, and enhances the therapeutic effect of anti-PD-L1 therapy (Bresser et al., 2022).

To date, over 20 CD47/SIRPα blocking agents have been employed in clinical trials (summarized in Table 1), involving in both hematological malignancies and solid tumors. However, the current clinical trial data of QPCTL inhibitors in antitumor treatment are lacking.

Although promising, the CD47-SIRPα blocking agents still face some challenges that restrict their translation to clinical settings. For instance, the ubiquitous expression of CD47 indicates that large dose or frequent administration of anti-CD47 antibodies is required (eg: antigen sink effect) (Chen et al., 2022), suggesting the efficacy of anti-CD47 antibodies treatment is relatively low. With regard to targeting bispecific antibodies of CD47 and CD47 antibodies/SIRPα fusion protein technology, while promising, it requires complex design and isolation (Chen et al., 2013; Labrijn et al., 2019). Therefore, the cost of these therapies is usually unaffordable for patients, which limits their clinical applications (Chen et al., 2013; Labrijn et al., 2019). As for SIRPα targeting strategy, it constantly fail to induce ADCP and ADCC against cancer cells when administrated alone due to immune cells target (Chen et al., 2013; Ring et al., 2017; Labrijn et al., 2019; Chen et al., 2022). The demand for safer and more efficient drug delivery is therefore increasing.

Nanomedicine, defined as the application of nanotechnology, can meet this need. Nanotechnology enables therapeutic drugs to target sites with high spatial and temporal resolution, prolonged half-life and great convenience for combination therapy. Therefore, CD47-SIRPα targeting based nanomedicine holds great potential in antitumor field, which will be reviewed in more detail in the following sections.

Overview of Nanomedicine

The efficacy of drugs has been limited, due to nonspecific distribution, side effects and short circulation time, offering an evolutionary opportunity for nanomedicine to circumvent these drawbacks and improve therapeutic efficacy. Diverse applications of nanomedicine have been investigated in multiple areas, such as drug delivery, vaccine development, diagnosis, and imaging tools (Pelaz et al., 2017). In this section, we mainly focus on the application of nanomedicine in drug delivery.

Type of Nanoparticles

Nanoparticles (NPs) are important components of nanomedicine. The unique characteristics of NPs, such as large surface-volume ratio, small size, capacity to encapsulate various drugs, and tunable surface chemistry, provides themselves a large variety of advantages, including multivalent surface modification, efficient navigation in vivo, increased intracellular trafficking and sustained release of drug payloads (Xu et al., 2015). Currently, diverse types of NPs exist, including liposomes (Huynh et al., 2009; Wang et al., 2016; Olusanya et al., 2018; Yang et al., 2021), micelles (Torchilin, 2007; Tawfik et al., 2020), poly (lactic-co-glycolic acid) (PLGA) (Sadat Tabatabaei Mirakabad et al., 2014; Rezvantalab et al., 2018), graphene (Diez-Pascual, 2020), graphene oxide (Kinnear et al., 2017; Diez-Pascual, 2020), protein nanoparticles (Lohcharoenkal et al., 2014; Jain et al., 2018), extracellular vesicles (EVs) (S et al., 2013; Si et al., 2022; Logozzi et al., 2021), exosomes (De La Peña et al., 2009; Nie et al., 2020; Xia et al., 2020; Logozzi et al., 2021), magnetic NPs (MNPs) (Colombo et al., 2012; Wu et al., 2019; Farzin et al., 2020), mesoporous silica NPs (MSNPs) (Fu et al., 2013; Wang et al., 2015; Pelaz et al., 2017; Rastegari et al., 2021), and metal-organ frameworks (MOFs) (Zheng et al., 2016; Wu and Yang, 2017; Xing et al., 2020), Ferritin (Lee et al., 2017; Cho et al., 2018; Sun et al., 2021). Detailed information about the charaterizations, advantages and disadvantages of each type of NP is summarized in Table 2. As summarized in Table 2, while each nanocarrier possesses unique merits, they still face certain problems that restrict their optimal performance in the drug delivery system.

Targeted Delivery Capacity of NPs

Targeted delivery capacity, including passive targeting and active targeting, is a key feature of nanomedicine and has been vastly studied.

Passive targeting is achieved by the enhanced permeability and retention (EPR) effect, prolonging the half-life of NPs in the body circulation (Maeda et al., 1999; Fang et al., 2003). Thus, prolonging the circulation time of NPs is a good strategy to increase their accumulation at the tumor site. The stealth modification of NPs is of great importance. Camouflaging the surface with polyethylene glycol (PEG) is the most common way to create a protective layer for encapsulated cargo by reducing the absorption of plasma proteins and extending the half-life of NPs (Gref et al., 2000). In addition to PEGylation, new biomaterials and drug delivery strategies have been developed to prolong the circulation time of NPs, including zwitterionic polymer-coating (Zhu et al., 2014), minimal self-peptides (e.g., CD47-derived self-peptides) (Rodriguez et al., 2013), and biomimetic membrane-coating (Hu et al., 2011). Nevertheless, passive targeting is far to reach the requirement of therapeutic efficacy. Due to the phagocytosis of mononuclear phagocytes, the majority (more than 90%) of NPs are inevitably entrapped by reticuloendithelial organs, such as liver and spleen (Albanese et al., 2012).

To overcome this severe drawback, measures that make nanomedicine actively target the disease site should be taken to increase the accumulation of drugs at the target site and subsequently enhance the therapeutic efficacy. Active targeting is a strategy to achieve the goal of orientation in space and simultaneously eliminates the off-target effect in normal tissues by intentionally guiding NPs to the disease site. A common approach to active targeting is to decorate the appropriate ligands to the surface of NPs. These ligands interact with the surface receptor of target cells inducing receptor-mediated endocytosis (Chen et al., 2017). Target agents can be broadly categorized as proteins (mainly antibodies and their fragments), nucleic acids (aptamers), or other receptor ligands (Peer et al., 2007).

Controlled Drug Release

To release the drug at a specific site and time, various efforts have been made to develop stimuli-responsive NPs, which further enhance the therapeutic efficacy (Li et al., 2020). These stimuli-responsive NPs can be stimulated by either endogenous stimuli-responsive strategies, such as pH variation, redox, enzyme, hypoxia, or exogenous stimuli-responsive strategies, such as light, ultrasound, magnetic field, temperature (Tawfik et al., 2020). However, these single stimuli-responsive strategies still face some challenges. For example, several temperatue- and light-responsive agents can damage normal cells and even tissues and organs (Wu et al., 2018). Due to insufficient H₂O₂ levels in tumor tissues, the nonspecificity and low therapeutic efficiency of H₂O₂-responsive nanoplatforms are also key challenges for clinical translation (Chang et al., 2017). Nanoassemblies activated by both exogenous stimuli and endogenous stimuli have gained tremendous attention by virtue of the enhanced encapsulated payload and the higher accuracy of spatiotemporal release. For instance, chen et al. developed a photothermal-PH-hypoxia responsive multifunctional nanoplatform (TENAB NP) for cancer photochemotherapy, for synergistic chemo-phototherapy with minimized skin photosensitization (Chen et al., 2019a). In this multistimuli responsive drug delivery system, tirapazamine, the hypoxia-specific prodrug, and ENAB, the pH-responsive photosensitizer, were encapsulated into the phase change materials (LASA), a mixture of linoleic acid and stearyl alcohol.

Role of the CD47-SIRPα Checkpoint in Nanomedicine-Based Disease Treatment

As previously described, systemic administration of CD47-SIRPα blocking agents has led to remarkable achievements, but the concomitant side effects (e.g., anemia) and limitations have restricted their translation to clinical use. To address these issues, nanotechnology has been introduced to reduce the side effects and enhance the stability and efficacy of the drug and the possibility of controlled release. In this section, we review the recent advances in the role of the CD47-SIRPα checkpoint in nanomedicine-based disease treatment.

Blocking the “Don’t Eat Me” Signal of the CD47-SIRPα Interaction

The upregulated CD47 on tumor cells increases its interaction with SIRPα on macrophages, resulting in an evasion of immunological surveillance and the muturation of DCs (Willingham et al., 2012; Jaiswal et al., 2009; Liu et al., 2015a; Liu et al., 2017). This inhibitory checkpoint paves the way for therapeutic strategies involving blocking this interaction to enhance innate and adaptive immunity for tumor killing (Figure 2). For instance, Koh et al. constructed an exosome through surface engineering with SIRPα variants termed SIRPα-exosomes, which can bind to both human and mouse CD47 as antagonists. The therapeutic efficacy of these engineered exosomes was verified in HT27 tumor-bearing mice (including immunodeficient and immunocompetent mice). Systemic administration of SIRPα-exosomes induced significant regression of tumor growth in immunocompetent mice, while tumor growth was slightly reduced in immunodeficient mice, suggesting that T-cell immunity might be essential to maximize the antitumor effect of CD47 blockade therapy (Koh et al., 2017). Ramesh et al. developed a multivalent lipid-based phagocytosis nanoenhancer with the conjugation of anti-CD47 and anti-SIRPα antibodies (LPN). LPN treatment showed remarkable tumor growth suppression and increased survival in B16F10 tumor-bearing mice with no systemic toxicity (Ramesh et al., 2020).

FIGURE 2

However, cancers are very complex diseases involving multiple pathways, and their progression is associated with various continuous mutations in cell lines. In addition, in order to survive, tumor cells mutate as chemotherapy progresses, thereby resulting in intrinsic and acquired resistance to chemotherapeutics (Iyer et al., 2013). Hence, the inhibition of the CD47-SIRPα signaling pathway is not sufficient to fight against tumor, and often requires a combination of blockades of different pathways, genes or chemotherapeutics (Xu et al., 2015). The advantages of nanomedicine, such as the capacity of encapsulating different drugs, targeted delivery and controlled release, offer a great opportunity for combination therapy for tumors. Some examples to show how the combination of blockade of the CD47-SIRPα interaction and other therapeutics or modalities works in nanomedicine are listed in Table 3 and explained in the next section.

Recent advances in tumor immunology suggest that the antitumor effect of blocking the CD47-SiRPα signaling pathway may be discounted by the immunosuppressive tumor microenvironment (TME) (Noy and Pollard, 2014; Chen et al., 2019b). In particular, colony-stimulating factors, secreted by tumor cells, are abundant in the TME, polarizing TAMs to the tumorigenic M2 phenotype (Noy and Pollard, 2014; Chen et al., 2019b). M2 TAMs can recruit regulatory T cells (Tregs) and secrete proinflammatory cytokines, all of which impair the activation of CD47 blockers against tumor T-cell immunity (Mantovani et al., 2017; Kulkarni et al., 2018; Feng et al., 2019). In this context, blocking the CD47-SIRPα signaling axis while polarizing tumorigenic M2- to anti-tumor M1-phenotype TAMs can improve the antitumor effect of CD47 immune checkpoint inhibitors (Ramesh et al., 2019; Rao et al., 2020a; Rao et al., 2020b; Chen et al., 2020; Nie et al., 2020; Chen et al., 2021; Huang et al., 2021). For example, Rao et al. have developed a genetically engineered cell-membrane-coated magnetic nanovehicle (gCM-MNs). The gCM shell genetically overexpressing SIRPα variants with prominent affinity and efficiently inhibits the CD47-SIRPα signaling axis, which can also protect the MN core from macrophage phagocytosis. The MN core promotes M2 TAM repolarization, synergistically triggering potent macrophage immune responses. Moreover, the MN core delivers the gCMs into tumor tissues under magnetic navigation, effectively promoting their tumor accumulation. In melanoma and triple-negative breast cancer models, gCM-MNs remarkably extended overall survival by inhibiting local tumor growth and distant metastasis (Rao et al., 2020a; Figure 3).

FIGURE 3

Many studies have investigated the efficacy of chemotherapy as an adjuvant to immunotherapy, suggesting that the most significant potential mechanism of such adjunct is immunogenic cell death (ICD) (Zitvogel et al., 2008; RA and BW, 2005; Hou et al., 2013). ICD has a number of clearly defined physiological characteristics, including cell surface CRT expression, release of DAMPs such as adenosine triphosphate and heat shock proteins, and release of high mobility group box 1 (Liu et al., 2016). Among these factors, the surface expression of CRT is considered to be the single most important element of ICD (Abdel-Bar et al., 2021). As previously mentioned, the effect of CRT exposure, serving as an “eat me” signal, is considered to be counterbalanced and potentially dampened by CD47 expression (Chao et al., 2010a). Moreover, the upregulated expression of CD47 on the surface of tumor cells makes it an active targeting site for tumor cells, facilitating nonspecific distributed ICD inducing drugs to target tumor tissues and reduce systemic toxicity (Tang et al., 2021). Therefore, codelivery, which simultaneously removes an inhibitory signal and introduces an activating signal, can produce an enhanced antitumor effect (Abdel-Bar et al., 2021; Lee et al., 2021). For example, Abdel-Bar et al. reported a stable nucleic acid-lipid particle (SNALP) formulation with the simultaneous delivery of an ICD inducing drug (Dox) with small interfering RNA (siRNA) knocking down CD47 (siCD47) for synergistic enhancement of ICD. In a CT-26-tumor-bearing mouse model, SNALPs synergistically inhibited tumor growth and prolonged the survival (Abdel-Bar et al., 2021).

EGFR is overexpressed in various solid tumors, such as breast, renal, colon, head and neck cancer (Normanno et al., 2001; Gazdar, 2009; Yu et al., 2013) Hence, EGFR targeting strategy is a promising way for antitumor treatment (Mendelsohn and Baselga, 2003; Yu et al., 2013; Sabbah et al., 2020). CD47 is also overexpressed on the surface of multiple tumor cells. Therefore, dual targeting to EGFR and CD47 strategy can efficiently target and inhibit tumor growth. For example, Si et al. constructed anti-EGFR/CD47 mAb marked EV which showed a high anti-TNBC efficacy with negligible toxicity in both 4T1 tumor-bearing mouse models and TNBC patient-derived xenograft models (Si et al., 2022).

Programmed cell death-ligand 1 (PD-L1) blockade therapy has achieved exciting success in the clinic (Pardoll, 2012). PD-L1, which is highly expressed in many tumor cells, sends a “don’t find me” signal to the adaptive immune system, inhibiting T-cell activation by engaging the PD-1 receptor (Parsa et al., 2007). CD47 sends a “don’t eat me” signal to the innate immune system, inhibiting the phagocytosis of macrophages by engaging SIRPα (Hayat et al., 2020; Logtenberg et al., 2020; Zhang et al., 2020). Hence, dual-blockade of PD-L1 and CD47 can activate potent antitumor effects via both innate and adaptive immune responses (Chen et al., 2019c; Lian et al., 2019; Meng et al., 2021; Pham et al., 2021; Zhao et al., 2021). For example, Meng et al. designed genetically programmable fusion cellular vesicles (Fus-CVs), which were fused by SIRPα variants and PD-1 variants. This bispecific targeting design improves the targeting of tumor cells while reducing the adverse off-target effect on normal cells. In malignant melanoma and mammary carcinoma models, Fus-CVs synergistically suppressed postsurgery tumor recurrence and metastasis, thereby improving overall survival (Meng et al., 2021).

PTT is a promising cancer treatment modality. PTT-induced hyperthermia can be controlled through the local use of photosensitizers and minimally invasive near-infrared (NIR) radiation to reduce damage to untargeted tissues (Sica et al., 2006; Chu and Dupuy, 2014; Chen et al., 2015). Recently, increasing studies have demonstrated that hyperthermia can induce dying tumor cells to release massive amounts of cytokines, such as IL-1β and TNF-α, promoting the immune responses of macrophages, NK cells and T lymphocytes. Yet, it is difficult to completely eradicate large tumors with conventional PTT due to residual tumor mass at the treatment margins (Mantovani et al., 2006; Chu and Dupuy, 2014; Shim et al., 2017). Therefore, researchers combined CD47 blockers with PTT to synergistically enhance the antitumor effect (Wu et al., 2015; Guo et al., 2019; Xie et al., 2020; Zhan et al., 2021). For example, Guo et al. reported bismuth selenide nanoparticles conjugated with anti-CD47 antibody and coated with PEG (Ab-PEG-Bi2Se3). In the 4T1 tumor-bearing model, Ab-PEG-Bi2Se3 plus PTT synergistically eradicate the tumor (Guo et al., 2019).

Utilizing the “Don’t Eat Me” Signal of the CD47-SIRPα Interaction

Reducing the capture of NPs by reticuloendothelial organs (such as liver, spleen, and lung) and extending their circulation time in the blood to accumulate more NPs in tumor tissues have been challenges. Currently, there are many approaches to prolong the half-life of NPs in blood, such as PEG surface modification and bionic membrane coating techniques described above. However, these approaches still have some disadvantages and limitations. Therefore, more suitable alternatives are urgently needed. The CD47 protein, as a “self” marker, can evade phagocytosis by the CD47-SIRPα interaction (Logtenberg et al., 2020). With regard to the pivotal role of CD47 in the regulation of immune responses, the present paper outlines emerging methods for the production of bioinert biomaterials and NPs using CD47 (Gheibi Hayat et al., 2019; Figure 4) Examples of stealth functionalization by CD47 mimicry utilized for antitumor nanomedicine are listed in Table 4 (Kamerkar et al., 2017; Shim et al., 2017; Jiang et al., 2018; Song et al., 2019; Wang et al., 2019; Belhadj et al., 2020; Cheng et al., 2021; Tang et al., 2021; Xie et al., 2021; Zhang et al., 2021). For instance, Tang et al. designed a precise delivery nanomedicine to M2 macrophages by combining “eat me/don’t eat me” signals and verified its role in antitumor therapy in an A20 subcutaneous tumor mouse model. In this delivery system, CD47-derived self-peptide ligand and galactose ligand were introduced on liposomes to reduce the phagocytosis of M1 macrophages and enhance the uptake of M2 macrophages, respectively. Cleavable phospholipid-PEG covering on the surface of liposomes can be removed by the redox microenvironment upon transcytosis through the tumor endothelium and re-expose the self-peptide and galactose. Therefore, this nanocarrier can precisely target M2-type TAMs. In addition, DOX loaded into liposomes further enhances its antitumor effect (Tang et al., 2021; Figure 5)

FIGURE 4

FIGURE 5

Conclusion and Limitations

CD47 is an inhibitory immune checkpoint that is highly expressed on tumor cells, binding with SIRPα on myeloid cells and thereby releasing a “don’t eat me” signal, inhibiting phagocytosis. On one hand, blocking the CD47-SIRPα signaling axis can activate macrophage phagocytosis of tumor cells and enhance the antigen presenting function of DC, subsequently bridging innate immune responses with the adaptive immune responses. Therefore, tumor immunotherapy focusing on the CD47-SIRPα axis has recently garnished significant attention. However, due to nonspecific targeting, systemic administration of CD47-SIRPα blockades can cause severe side effects, which provides the development of nanomedicine a great opportunity. On the other hand, researchers make use of this negative regulatory effect of the CD47-SIRPα axis to decorate the NPs with a stealthy function, markedly increasing both circulation time and drug uptake by tumor cells. Due to the high plasticity and selectivity of nanomaterials, they can be used as therapeutic agents (such as CD47-rich vesicles) and drug delivery vehicles of any site of the CD47-SiRPα signaling axis. It offers great convenience for the realization of targeted therapy, combination therapy and the improvement of antitumor effect.

Although anticancer nanomedicine focusing on this signaling axis has extensive prospects, there are still many challenges to be overcome to realize full practical applications. For example, understanding of the CD47-SiRPα signal axis is not thorough enough, such as how to properly regulate the intensity of this signal axis in the spatiotemporal category. In addition, the synthesis of ideal NPs is complex and difficult. As mentioned earlier, small changes in any part of the NP manufacturing process can lead to large changes in the performance of nanomedicines. This sensitivity requires the knowledge of nanomaterials and rigor in the fabrication process. The harm of nanomaterials cannot be neglected. Last but not least, regarding combination therapy, control of the drug loading ratio and the spatiotemporal order of drug release are problems to be solved.

Nevertheless, these challenges can also be opportunities. With the deepening of researchers’ knowledge of the CD47-SiRPα pathway and tumor nanomedical science, the perfect combination of increasingly mature nanotechnology and body pathology and physiology in the future will achieve better clinical transformation.

Data AvailabilityStatement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

References

• 1

  Abdel-BarH. M.WaltersA. A.LimY.RouatbiN.QinY.GheidariF.et al (2021). An "eat Me" Combinatory Nano-Formulation for Systemic Immunotherapy of Solid Tumors. Theranostics11 (18), 8738–8754. 10.7150/thno.56936

  • CrossRef
  • Google Scholar

• 2

  AdamsS.van der LaanL. J.Vernon-WilsonE.Renardel de LavaletteC.DöppE. A.DijkstraC. D., Signal-regulatory Protein Is Selectively Expressed by Myeloid and Neuronal Cells. J. Immun., 161(4), 1853–1859. (1998).

  • Google Scholar

• 3

  AdvaniR.FlinnI.PopplewellL.ForeroA.BartlettN. L.GhoshN.et al (2018). CD47 Blockade by Hu5F9-G4 and Rituximab in Non-hodgkin's Lymphoma. N. Engl. J. Med.379 (18), 1711–1721. 10.1056/NEJMoa1807315

  • CrossRef
  • Google Scholar

• 4

  AlbaneseA.TangP. S.ChanW. C. (2012). The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems. Annu. Rev. Biomed. Eng.14, 1–16. 10.1146/annurev-bioeng-071811-150124

  • CrossRef
  • Google Scholar

• 5

  AndrejevaG.CapocciaB. J.HiebschR. R.DonioM. J.DarwechI. M.PuroR. J.et al (2021). Novel SIRPalpha Antibodies that Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells. J. Immunol.206 (4), 712–721. 10.4049/jimmunol.2001019

  • CrossRef
  • Google Scholar

• 6

  BarclayA. N. (2009). Signal Regulatory Protein Alpha (SIRPα)/CD47 Interaction and Function. Curr. Opin. Immunol.21 (1), 47–52. 10.1016/j.coi.2009.01.008

  • CrossRef
  • Google Scholar

• 7

  BelhadjZ.HeB.DengH.SongS.ZhangH.WangX.et al (2020). A Combined "eat Me/don't Eat Me" Strategy Based on Extracellular Vesicles for Anticancer Nanomedicine. J. Extracell Vesicles9 (1), 1806444. 10.1080/20013078.2020.1806444

  • CrossRef
  • Google Scholar

• 8

  BresserK.LogtenbergM. E. W.ToebesM.ProostN.SprengersJ.SiteurB.et al (2022). QPCTL Regulates Macrophage and Monocyte Abundance and Inflammatory Signatures in the Tumor Microenvironment. Oncoimmunology11 (1), 2049486. 10.1080/2162402X.2022.2049486

  • CrossRef
  • Google Scholar

• 9

  BrownE.FrazierW. A. (2001). Integrin-associated Protein (CD47) and its Ligands. Trends. Cel Biol.11 (3), 130–135. 10.1016/s0962-8924(00)01906-1

  • CrossRef
  • Google Scholar

• 10

  ChangK.LiuZ.FangX.ChenH.MenX.YuanY.et al (2017). Enhanced Phototherapy by Nanoparticle-Enzyme via Generation and Photolysis of Hydrogen Peroxide. Nano Lett.17 (7), 4323–4329. 10.1021/acs.nanolett.7b01382

  • CrossRef
  • Google Scholar

• 11

  ChaoM. P.AlizadehA. A.TangC.MyklebustJ. H.VargheseB.GillS.et al (2010). Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-hodgkin Lymphoma. Cell142 (5), 699–713. 10.1016/j.cell.2010.07.044

  • CrossRef
  • Google Scholar

• 12

  ChaoM. P.JaiswalS.Weissman-TsukamotoR.AlizadehA. A.GentlesA. J.VolkmerJ.et al (2010). Calreticulin Is the Dominant Pro-phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47. Sci. Transl Med.2 (63), 63ra94. 10.1126/scitranslmed.3001375

  • CrossRef
  • Google Scholar

• 13

  ChenC.LiA.SunP.XuJ.DuW.ZhangJ.et al (2020). Efficiently Restoring the Tumoricidal Immunity against Resistant Malignancies via an Immune Nanomodulator. J. Control. Release324, 574–585. 10.1016/j.jconrel.2020.05.039

  • CrossRef
  • Google Scholar

• 14

  ChenD.TangY.ZhuJ.ZhangJ.SongX.WangW.et al (2019). Photothermal-pH-hypoxia Responsive Multifunctional Nanoplatform for Cancer Photo-Chemo Therapy with Negligible Skin Phototoxicity. Biomaterials221, 119422. 10.1016/j.biomaterials.2019.119422

  • CrossRef
  • Google Scholar

• 15

  ChenH.DiY.ChenD.MadridK.ZhangM.TianC.et al (2015). Combined Chemo- and Photo-thermal Therapy Delivered by Multifunctional Theranostic Gold Nanorod-Loaded Microcapsules. Nanoscale7 (19), 8884–8897. 10.1039/c5nr00473j

  • CrossRef
  • Google Scholar

• 16

  ChenM.DaddyJ. C. K.XiaoY.PingQ.ZongL. (2017). Advanced Nanomedicine for Rheumatoid Arthritis Treatment: Focus on Active Targeting. Expert Opin. Drug Deliv.14 (10), 1141–1144. 10.1080/17425247.2017.1372746

  • CrossRef
  • Google Scholar

• 17

  ChenM.MiaoY.QianK.ZhouX.GuoL.QiuY.et al (2021). Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages. Nano Lett.21 (14), 6031–6041. 10.1021/acs.nanolett.1c01210

  • CrossRef
  • Google Scholar

• 18

  ChenQ.ChenG.ChenJ.ShenJ.ZhangX.WangJ.et al (2019). Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy. Nano Lett.19 (8), 4879–4889. 10.1021/acs.nanolett.9b00584

  • CrossRef
  • Google Scholar

• 19

  ChenQ.WangC.ZhangX.ChenG.HuQ.LiH.et al (2019). In Situ sprayed Bioresponsive Immunotherapeutic Gel for post-surgical Cancer Treatment. Nat. Nanotechnol14 (1), 89–97. 10.1038/s41565-018-0319-4

  • CrossRef
  • Google Scholar

• 20

  ChenX.ZaroJ. L.ShenW. C. (2013). Fusion Protein Linkers: Property, Design and Functionality. Adv. Drug Deliv. Rev.65 (10), 1357–1369. 10.1016/j.addr.2012.09.039

  • CrossRef
  • Google Scholar

• 21

  ChenY. C.ShiW.ShiJ. J.LuJ. J. (2022). Progress of CD47 Immune Checkpoint Blockade Agents in Anticancer Therapy: a Hematotoxic Perspective. J. Cancer Res. Clin. Oncol.148 (1), 1–14. 10.1007/s00432-021-03815-z

  • CrossRef
  • Google Scholar

• 22

  ChengL.ZhangX.TangJ.LvQ.LiuJ. (2021). Gene-engineered Exosomes-Thermosensitive Liposomes Hybrid Nanovesicles by the Blockade of CD47 Signal for Combined Photothermal Therapy and Cancer Immunotherapy. Biomaterials275, 120964. 10.1016/j.biomaterials.2021.120964

  • CrossRef
  • Google Scholar

• 23

  ChoE.NamG. H.HongY.KimY. K.KimD. H.YangY.et al (2018). Comparison of Exosomes and Ferritin Protein Nanocages for the Delivery of Membrane Protein Therapeutics. J. Control. Release279, 326–335. 10.1016/j.jconrel.2018.04.037

  • CrossRef
  • Google Scholar

• 24

  ChuK. F.DupuyD. E. (2014). Thermal Ablation of Tumours: Biological Mechanisms and Advances in Therapy. Nat. Rev. Cancer14 (3), 199–208. 10.1038/nrc3672

  • CrossRef
  • Google Scholar

• 25

  ColomboM.Carregal-RomeroS.CasulaM. F.GutierrezL.MoralesM. P.BohmI. B.et al (2012). Biological Applications of Magnetic Nanoparticles. Chem. Soc. Rev.41 (11), 4306–4334. 10.1039/c2cs15337h

  • CrossRef
  • Google Scholar

• 26

  De La PeñaH.MadrigalJ. A.RusakiewiczS.BencsikM.CaveG. W. V.SelmanA.et al (2009). Artificial Exosomes as Tools for Basic and Clinical Immunology. J. Immunological Methods344 (2), 121–132. 10.1016/j.jim.2009.03.011

  • CrossRef
  • Google Scholar

• 27

  DheillyE.MoineV.BroyerL.Salgado-PiresS.JohnsonZ.PapaioannouA.et al (2017). Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies. Mol. Ther.25 (2), 523–533. 10.1016/j.ymthe.2016.11.006

  • CrossRef
  • Google Scholar

• 28

  Diez-PascualA. M. (2020). Antibacterial Action of Nanoparticle Loaded Nanocomposites Based on Graphene and its Derivatives: A Mini-Review. Int. J. Mol. Sci.21 (10). 3563. 10.3390/ijms21103563

  • CrossRef
  • Google Scholar

• 29

  FangJ.SawaT.MaedaH. (2003). Factors and Mechanism of "EPR" Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS. Adv. Exp. Med. Biol.519, 29–49. 10.1007/0-306-47932-X_2

  • CrossRef
  • Google Scholar

• 30

  FarzinA.EtesamiS. A.QuintJ.MemicA.TamayolA. (2020). Magnetic Nanoparticles in Cancer Therapy and Diagnosis. Adv. Healthc. Mater.9 (9). 147. 10.1002/adhm.201901058

  • CrossRef
  • Google Scholar

• 31

  FengM.JiangW.KimB. Y. S.ZhangC. C.FuY. X.WeissmanI. L. (2019). Phagocytosis Checkpoints as New Targets for Cancer Immunotherapy. Nat. Rev. Cancer19 (10), 568–586. 10.1038/s41568-019-0183-z

  • CrossRef
  • Google Scholar

• 32

  FuC.LiuT.LiL.LiuH.ChenD.TangF. (2013). The Absorption, Distribution, Excretion and Toxicity of Mesoporous Silica Nanoparticles in Mice Following Different Exposure Routes. Biomaterials34 (10), 2565–2575. 10.1016/j.biomaterials.2012.12.043

  • CrossRef
  • Google Scholar

• 33

  GazdarA. F. (2009). Activating and Resistance Mutations of EGFR in Non-small-cell Lung Cancer: Role in Clinical Response to EGFR Tyrosine Kinase Inhibitors. Oncogene28 (Suppl. 1), S24–S31. 10.1038/onc.2009.198

  • CrossRef
  • Google Scholar

• 34

  Gheibi HayatS. M.BianconiV.PirroM.SahebkarA. (2019). Stealth Functionalization of Biomaterials and Nanoparticles by CD47 Mimicry. Int. J. Pharm.569, 118628. 10.1016/j.ijpharm.2019.118628

  • CrossRef
  • Google Scholar

• 35

  GholaminS.MitraS. S.FerozeA. H.LiuJ.KahnS. A.ZhangM. (2017). Disrupting the CD47-Sirpα Anti-phagocytic axis by a Humanized Anti-CD47 Antibody Is an Efficacious Treatment for Malignant Pediatric Brain Tumors. Sci. Transl9 (381), eaaf2968. 10.1126/scitranslmed.aaf2968

  • CrossRef
  • Google Scholar

• 36

  GrefR.LückM.QuellecP.MarchandM.DellacherieE.HarnischS. (2000). ‘Stealth’ corona-core Nanoparticles Surface Modified by Polyethylene Glycol (PEG) Influences of the corona (PEG Chain Length and Surface Density) and of the Core Composition on Phagocytic Uptake and Plasma Protein Adsorptio. Colloids Surf. B Biointerfaces18 (3-4), 301–313. 10.1016/s0927-7765(99)00156-3

  • CrossRef
  • Google Scholar

• 37

  GuoZ.LiuY.ZhouH.ZhengK.WangD.JiaM.et al (2019). CD47-targeted Bismuth Selenide Nanoparticles Actualize Improved Photothermal Therapy by Increasing Macrophage Phagocytosis of Cancer Cells. Colloids Surf. B Biointerfaces184, 110546. 10.1016/j.colsurfb.2019.110546

  • CrossRef
  • Google Scholar

• 38

  HayatS. M. G.BianconiV.PirroM.JaafariM. R.HatamipourM.SahebkarA. (2020). CD47: Role in the Immune System and Application to Cancer Therapy. Cell Oncol.43 (1), 19–30. 10.1007/s13402-019-00469-5

  • CrossRef
  • Google Scholar

• 39

  HoC. C. M.GuoN.SockoloskyJ. T.RingA. M.WeiskopfK.ÖzkanE.et al (2015). "Velcro" Engineering of High Affinity CD47 Ectodomain as Signal Regulatory Protein α (SIRPα) Antagonists that Enhance Antibody-dependent Cellular Phagocytosis. J. Biol. Chem.290 (20), 12650–12663. 10.1074/jbc.M115.648220

  • CrossRef
  • Google Scholar

• 40

  HouW.ZhangQ.YanZ.ChenR.ZehH. J.IiiKangR.et al (2013). Strange Attractors: DAMPs and Autophagy Link Tumor Cell Death and Immunity. Cell Death Dis4, e966. 10.1038/cddis.2013.493

  • CrossRef
  • Google Scholar

• 41

  HuC. M.ZhangL.AryalS.CheungC.FangR. H.ZhangL. (2011). Erythrocyte Membrane-Camouflaged Polymeric Nanoparticles as a Biomimetic Delivery Platform. Proc. Natl. Acad. Sci. U S A.108 (27), 10980–10985. 10.1073/pnas.1106634108

  • CrossRef
  • Google Scholar

• 42

  HuangL.ZhangY.LiY.MengF.LiH.ZhangH.et al (2021). Time-Programmed Delivery of Sorafenib and Anti-CD47 Antibody via a Double-Layer-Gel Matrix for Postsurgical Treatment of Breast Cancer. Nanomicro Lett.13 (1), 141. 10.1007/s40820-021-00647-x

  • CrossRef
  • Google Scholar

• 43

  HuynhN. T.PassiraniC.SaulnierP.BenoitJ. P. (2009). Lipid Nanocapsules: a New Platform for Nanomedicine. Int. J. Pharm.379 (2), 201–209. 10.1016/j.ijpharm.2009.04.026

  • CrossRef
  • Google Scholar

• 44

  IngramJ. R.BlombergO. S.SockoloskyJ. T.AliL.SchmidtF. I.PisheshaN.et al (2017). Localized CD47 Blockade Enhances Immunotherapy for Murine Melanoma. Proc. Natl. Acad. Sci. U S A.114 (38), 10184–10189. 10.1073/pnas.1710776114

  • CrossRef
  • Google Scholar

• 45

  IyerA. K.SinghA.GantaS.AmijiM. M. (2013). Role of Integrated Cancer Nanomedicine in Overcoming Drug Resistance. Adv. Drug Deliv. Rev.65 (13-14), 1784–1802. 10.1016/j.addr.2013.07.012

  • CrossRef
  • Google Scholar

• 46

  JainA.SinghS. K.AryaS. K.KunduS. C.KapoorS. (2018). Protein Nanoparticles: Promising Platforms for Drug Delivery Applications. ACS Biomater. Sci. Eng.4 (12), 3939–3961. 10.1021/acsbiomaterials.8b01098

  • CrossRef
  • Google Scholar

• 47

  JaiswalS.JamiesonC. H. M.PangW. W.ParkC. Y.ChaoM. P.MajetiR.et al (2009). CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis. Cell138 (2), 271–285. 10.1016/j.cell.2009.05.046

  • CrossRef
  • Google Scholar

• 48

  JiangZ.TianY.ShanD.WangY.GerhardE.XiaJ.et al (2018). pH Protective Y1 Receptor Ligand Functionalized Antiphagocytosis BPLP-WPU Micelles for Enhanced Tumor Imaging and Therapy with Prolonged Survival Time. Biomaterials170, 70–81. 10.1016/j.biomaterials.2018.04.002

  • CrossRef
  • Google Scholar

• 49

  KamerkarS.LeBleuV. S.SugimotoH.YangS.RuivoC. F.MeloS. A.et al (2017). Exosomes Facilitate Therapeutic Targeting of Oncogenic KRAS in Pancreatic Cancer. Nature546 (7659), 498–503. 10.1038/nature22341

  • CrossRef
  • Google Scholar

• 50

  KinnearC.MooreT. L.Rodriguez-LorenzoL.Rothen-RutishauserB.Petri-FinkA. (2017). Form Follows Function: Nanoparticle Shape and its Implications for Nanomedicine. Chem. Rev.117 (17), 11476–11521. 10.1021/acs.chemrev.7b00194

  • CrossRef
  • Google Scholar

• 51

  KohE.LeeE. J.NamG. H.HongY.ChoE.YangY.et al (2017). Exosome-SIRPalpha, a CD47 Blockade Increases Cancer Cell Phagocytosis. Biomaterials121, 121–129. 10.1016/j.biomaterials.2017.01.004

  • CrossRef
  • Google Scholar

• 52

  KulkarniA.ChandrasekarV.NatarajanS. K.RameshA.PandeyP.NirgudJ.et al (2018). A Designer Self-Assembled Supramolecule Amplifies Macrophage Immune Responses against Aggressive Cancer. Nat. Biomed. Eng.2 (8), 589–599. 10.1038/s41551-018-0254-6

  • CrossRef
  • Google Scholar

• 53

  LabrijnA. F.JanmaatM. L.ReichertJ. M.ParrenP. (2019). Bispecific Antibodies: a Mechanistic Review of the Pipeline. Nat. Rev. Drug Discov.18 (8), 585–608. 10.1038/s41573-019-0028-1

  • CrossRef
  • Google Scholar

• 54

  LatourS.TanakaH.DemeureC.MateoV.RubioM.BrownE. J.et al (2001). Bidirectional Negative Regulation of Human T and Dendritic Cells by CD47 and its Cognate Receptor Signal-Regulator Protein-α: Down-Regulation of IL-12 Responsiveness and Inhibition of Dendritic Cell Activation. J. Immunol.167 (5), 2547–2554. 10.4049/jimmunol.167.5.2547

  • CrossRef
  • Google Scholar

• 55

  LeeN. K.ChoiJ. U.KimH. R.ChungS. W.KoY. G.ChoY. S.et al (2021). Caspase-cleavable Peptide-Doxorubicin Conjugate in Combination with CD47-Antagonizing Nanocage Therapeutics for Immune-Mediated Elimination of Colorectal Cancer. Biomaterials277, 121105. 10.1016/j.biomaterials.2021.121105

  • CrossRef
  • Google Scholar

• 56

  LeeN. K.LeeE. J.KimS.NamG. H.KihM.HongY.et al (2017). Ferritin Nanocage with Intrinsically Disordered Proteins and Affibody: a Platform for Tumor Targeting with Extended Pharmacokinetics. J. Control Release267, 172–180. 10.1016/j.jconrel.2017.08.014

  • CrossRef
  • Google Scholar

• 57

  LiF.QinY.LeeJ.LiaoH.WangN.DavisT. P.et al (2020). Stimuli-responsive Nano-Assemblies for Remotely Controlled Drug Delivery. J. Control. Release322, 566–592. 10.1016/j.jconrel.2020.03.051

  • CrossRef
  • Google Scholar

• 58

  LianS.XieR.YeY.XieX.LiS.LuY.et al (2019). Simultaneous Blocking of CD47 and PD-L1 Increases Innate and Adaptive Cancer Immune Responses and Cytokine Release. EBioMedicine42, 281–295. 10.1016/j.ebiom.2019.03.018

  • CrossRef
  • Google Scholar

• 59

  LindbergF. P.BullardD. C.CaverT. E.GreshamH. D.BeaudetA. L.BrownE. J. (1996). Decreased Resistance to Bacterial Infection and Granulocyte Defects in IAP-Deficient Mice. Science274 (5288), 795–798. 10.1126/science.274.5288.795

  • CrossRef
  • Google Scholar

• 60

  LiuC. C.LeclairP.MonajemiM.SlyL. M.ReidG. S.LimC. J. (2016). Alpha-Integrin Expression and Function Modulates Presentation of Cell Surface Calreticulin. Cel Death Dis7, e2268. 10.1038/cddis.2016.176

  • CrossRef
  • Google Scholar

• 61

  LiuJ.WangL.ZhaoF.TsengS.NarayananC.ShuraL.et al (2015). Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-cancer Therapeutic Potential. PLoS One10 (9), e0137345. 10.1371/journal.pone.0137345

  • CrossRef
  • Google Scholar

• 62

  LiuX.KwonH.LiZ.FuY. X. (2017). Is CD47 an Innate Immune Checkpoint for Tumor Evasion?J. Hematol. Oncol.10 (1), 12. 10.1186/s13045-016-0381-z

  • CrossRef
  • Google Scholar

• 63

  LiuX.PuY.CronK.DengL.KlineJ.FrazierW. A.et al (2015). CD47 Blockade Triggers T Cell-Mediated Destruction of Immunogenic Tumors. Nat. Med.21 (10), 1209–1215. 10.1038/nm.3931

  • CrossRef
  • Google Scholar

• 64

  LiuY.MerlinD.BurstS. L.PochetM.MadaraJ. L.ParkosC. A. (2001). The Role of CD47 in Neutrophil Transmigration. J. Biol. Chem.276 (43), 40156–40166. 10.1074/jbc.M104138200

  • CrossRef
  • Google Scholar

• 65

  LogozziM.Di RaimoR.MizzoniD.FaisS. (2021). What We Know on the Potential Use of Exosomes for Nanodelivery. Semin. Cancer Biol.579X (21), 00229-7. 10.1016/j.semcancer.2021.09.005

  • CrossRef
  • Google Scholar

• 66

  LogtenbergM. E. W.JansenJ. H. M.RaabenM.ToebesM.FrankeK.BrandsmaA. M.et al (2019). Glutaminyl Cyclase Is an Enzymatic Modifier of the CD47- SIRPalpha axis and a Target for Cancer Immunotherapy. Nat. Med.25 (4), 612–619. 10.1038/s41591-019-0356-z

  • CrossRef
  • Google Scholar

• 67

  LogtenbergM. E. W.ScheerenF. A.SchumacherT. N. (2020). The CD47-Sirpα Immune Checkpoint. Immunity52 (5), 742–752. 10.1016/j.immuni.2020.04.011

  • CrossRef
  • Google Scholar

• 68

  LohcharoenkalW.WangL.ChenY. C.RojanasakulY. (2014). Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy. Biomed. Res. Int.2014, 180549. 10.1155/2014/180549

  • CrossRef
  • Google Scholar

• 69

  LutzH. U.BogdanovaA. (2013). Mechanisms Tagging Senescent Red Blood Cells for Clearance in Healthy Humans. Front. Physiol.4, 387. 10.3389/fphys.2013.00387

  • CrossRef
  • Google Scholar

• 70

  LymnJ. S.PatelM. K.ClunnG. F.RaoS. J.GallagherK. L.HughesA. D. (2002). Thrombospondin-1 Differentially Induces Chemotaxis and DNA Synthesis of Human Venous Smooth Muscle Cells at the Receptor-Binding Level. J. Cel Sci115 (Pt 22), 4353–4360. 10.1242/jcs.00119

  • CrossRef
  • Google Scholar

• 71

  MaedaH.WuJ.SawaT.MatsumuraY.HoriK. (1999). Tumor Vascular Permeability and the EPR Effect in Macromolecular Therapeutics: a Review. J. Control. Release65 (1-2), 271–284. 10.1016/s0168-3659(99)00248-5

  • CrossRef
  • Google Scholar

• 72

  MaileL. A.DeMambroV. E.WaiC.AdayA. W.CappsB. E.BeamerW. G.et al (2011). An Essential Role for the Association of CD47 to SHPS-1 in Skeletal Remodeling. J. Bone Miner Res.26 (9), 2068–2081. 10.1002/jbmr.441

  • CrossRef
  • Google Scholar

• 73

  MajetiR.ChaoM. P.AlizadehA. A.PangW. W.JaiswalS.GibbsK. D.Jr.et al (2009). CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. Cell138 (2), 286–299. 10.1016/j.cell.2009.05.045

  • CrossRef
  • Google Scholar

• 74

  MantovaniA.MarchesiF.MalesciA.LaghiL.AllavenaP. (2017). Tumour-associated Macrophages as Treatment Targets in Oncology. Nat. Rev. Clin. Oncol.14 (7), 399–416. 10.1038/nrclinonc.2016.217

  • CrossRef
  • Google Scholar

• 75

  MantovaniA.SchioppaT.PortaC.AllavenaP.SicaA. (2006). Role of Tumor-Associated Macrophages in Tumor Progression and Invasion. Cancer Metastasis Rev.25 (3), 315–322. 10.1007/s10555-006-9001-7

  • CrossRef
  • Google Scholar

• 76

  MendelsohnJ.BaselgaJ. (2003). Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer. J. Clin. Oncol.21 (14), 2787–2799. 10.1200/JCO.2003.01.504

  • CrossRef
  • Google Scholar

• 77

  MengQ. F.ZhaoY.DongC.LiuL.PanY.LaiJ.et al (2021). Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy. Angew. Chem. Int. Ed. Engl.60 (50), 26320–26326. 10.1002/anie.202108342

  • CrossRef
  • Google Scholar

• 78

  MengZ.WangZ.GuoB.CaoW.ShenH. (2019). TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties. Blood134 (Suppl. ment_1), 4063. 10.1182/blood-2019-122793

  • CrossRef
  • Google Scholar

• 79

  MushegianA. (2002). Refining Structural and Functional Predictions for Secretasome Components by Comparative Sequence Analysis. Proteins47 (1), 69–74. 10.1002/prot.10073

  • CrossRef
  • Google Scholar

• 80

  NieW.WuG.ZhangJ.HuangL. L.DingJ.JiangA.et al (2020). Responsive Exosome Nano-Bioconjugates for Synergistic Cancer Therapy. Angew. Chem. Int. Ed. Engl.59 (5), 2018–2022. 10.1002/anie.201912524

  • CrossRef
  • Google Scholar

• 81

  NormannoN.BiancoC.De LucaA.SalomonD. S. (2001). The Role of EGF-Related Peptides in Tumor Growth. Front. Biosci.6, D685–D707. 10.2741/normano

  • CrossRef
  • Google Scholar

• 82

  NoyR.PollardJ. W. (2014). Tumor-associated Macrophages: from Mechanisms to Therapy. Immunity41 (1), 49–61. 10.1016/j.immuni.2014.06.010

  • CrossRef
  • Google Scholar

• 83

  OldenborgP.-A.ZheleznyakA.FangY.-F.LagenaurC. F.GreshamH. D.LindbergF. P. (2000). Role of CD47 as a Marker of Self on Red Blood Cells. Science288 (5473), 2051–2054. 10.1126/science.288.5473.2051

  • CrossRef
  • Google Scholar

• 84

  OldenborgP. A.GreshamH. D.LindbergF. P. (2001). CD47-signal Regulatory Protein α (Sirpα) Regulates Fcγ and Complement Receptor–Mediated Phagocytosis. J. Exp. Med.193 (7), 855–861. 10.1084/jem.193.7.855

  • CrossRef
  • Google Scholar

• 85

  OlusanyaT.Haj AhmadR.IbegbuD.SmithJ.ElkordyA. (2018). Liposomal Drug Delivery Systems and Anticancer Drugs. Molecules23 (4). 10.3390/molecules23040907

  • CrossRef
  • Google Scholar

• 86

  PardollD. M. (2012). The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nat. Rev. Cancer12 (4), 252–264. 10.1038/nrc3239

  • CrossRef
  • Google Scholar

• 87

  ParsaA. T.WaldronJ. S.PannerA.CraneC. A.ParneyI. F.BarryJ. J.et al (2007). Loss of Tumor Suppressor PTEN Function Increases B7-H1 Expression and Immunoresistance in Glioma. Nat. Med.13 (1), 84–88. 10.1038/nm1517

  • CrossRef
  • Google Scholar

• 88

  PeerD.KarpJ. M.HongS.FarokhzadO. C.MargalitR.LangerR. (2007). Nanocarriers as an Emerging Platform for Cancer Therapy. Nat. Nanotechnol2 (12), 751–760. 10.1038/nnano.2007.387

  • CrossRef
  • Google Scholar

• 89

  PelazB.AlexiouC.Alvarez-PueblaR. A.AlvesF.AndrewsA. M.AshrafS.et al (2017). Diverse Applications of Nanomedicine. ACS Nano11 (3), 2313–2381. 10.1021/acsnano.6b06040

  • CrossRef
  • Google Scholar

• 90

  PetrovaP. S.VillerN. N.WongM.PangX.LinG. H. Y.DodgeK.et al (2017). TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin. Cancer Res.23 (4), 1068–1079. 10.1158/1078-0432.CCR-16-1700

  • CrossRef
  • Google Scholar

• 91

  PhamL. M.PoudelK.PhungC. D.NguyenT. T.PanditM.NguyenH. T.et al (2021). Preparation and Evaluation of Dabrafenib-Loaded, CD47-Conjugated Human Serum Albumin-Based Nanoconstructs for Chemoimmunomodulation. Colloids Surf. B Biointerfaces208, 112093. 10.1016/j.colsurfb.2021.112093

  • CrossRef
  • Google Scholar

• 92

  PuroR. J.BouchlakaM. N.HiebschR. R.CapocciaB. J.DonioM. J.ManningP. T.et al (2020). Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol. Cancer Ther.19 (3), 835–846. 10.1158/1535-7163.MCT-19-1079

  • CrossRef
  • Google Scholar

• 93

  RaL.BwR. (2005). Immunotherapy and Chemotherapy-Aa Practical Partnership. Nat. Rev. Cancer5 (5), 397–405. 10.1038/nrc1613

  • CrossRef
  • Google Scholar

• 94

  RameshA.KumarS.NandiD.KulkarniA. (2019). CSF1R- and SHP2-Inhibitor-Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor-Associated Macrophages. Adv. Mater.31 (51), e1904364. 10.1002/adma.201904364

  • CrossRef
  • Google Scholar

• 95

  RameshA.KumarS.NguyenA.BrouillardA.KulkarniA. (2020). Lipid-based Phagocytosis Nanoenhancer for Macrophage Immunotherapy. Nanoscale12 (3), 1875–1885. 10.1039/c9nr08670f

  • CrossRef
  • Google Scholar

• 96

  RaoL.WuL.LiuZ.TianR.YuG.ZhouZ.et al (2020). Hybrid Cellular Membrane Nanovesicles Amplify Macrophage Immune Responses against Cancer Recurrence and Metastasis. Nat. Commun.11 (1), 4909. 10.1038/s41467-020-18626-y

  • CrossRef
  • Google Scholar

• 97

  RaoL.ZhaoS. K.WenC.TianR.LinL.CaiB.et al (2020). Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles. Adv. Mater.32 (47), e2004853. 10.1002/adma.202004853

  • CrossRef
  • Google Scholar

• 98

  RastegariE.HsiaoY. J.LaiW. Y.LaiY. H.YangT. C.ChenS. J.et al (2021). An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine. Pharmaceutics13 (7). 1067. 10.3390/pharmaceutics13071067

  • CrossRef
  • Google Scholar

• 99

  RezvantalabS.DrudeN. I.MoravejiM. K.GuvenerN.KoonsE. K.ShiY.et al (2018). PLGA-based Nanoparticles in Cancer Treatment. Front. Pharmacol.9, 1260. 10.3389/fphar.2018.01260

  • CrossRef
  • Google Scholar

• 100

  RingN. G.Herndler-BrandstetterD.WeiskopfK.ShanL.VolkmerJ. P.GeorgeB. M.et al (2017). Anti-SIRPalpha Antibody Immunotherapy Enhances Neutrophil and Macrophage Antitumor Activity. Proc. Natl. Acad. Sci. U S A.114 (49), E10578–E10585. 10.1073/pnas.1710877114

  • CrossRef
  • Google Scholar

• 101

  RodriguezP. L.HaradaT.ChristianD. A.PantanoD. A.TsaiR. K.DischerD. E. (2013). Minimal "Self" Peptides that Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles. Science339 (6122), 971–975. 10.1126/science.1229568

  • CrossRef
  • Google Scholar

• 102

  SE. L. A.MagerI.BreakefieldX. O.WoodM. J. (2013). Extracellular Vesicles: Biology and Emerging Therapeutic Opportunities. Nat. Rev. Drug Discov.12 (5), 347–357. 10.1038/nrd3978

  • CrossRef
  • Google Scholar

• 103

  SabbahD. A.HajjoR.SweidanK. (2020). Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Curr. Top. Med. Chem.20 (10), 815–834. 10.2174/1568026620666200303123102

  • CrossRef
  • Google Scholar

• 104

  Sadat Tabatabaei MirakabadF.Nejati-KoshkiK.AkbarzadehA.YamchiM. R.MilaniM.ZarghamiN.et al (2014). PLGA-based Nanoparticles as Cancer Drug Delivery Systems. Asian Pac. J. Cancer Prev.15 (2), 517–535. 10.7314/apjcp.2014.15.2.517

  • CrossRef
  • Google Scholar

• 105

  ShiR.ChaiY.DuanX.BiX.HuangQ.WangQ.et al (2020). The Identification of a CD47-Blocking "hotspot" and Design of a CD47/PD-L1 Dual-specific Antibody with Limited Hemagglutination. Signal. Transduct Target. Ther.5 (1), 16. 10.1038/s41392-020-0121-2

  • CrossRef
  • Google Scholar

• 106

  ShimG.MiaoW.KoS.ParkG. T.KimJ. Y.KimM. G.et al (2017). Immune-camouflaged Graphene Oxide Nanosheets for Negative Regulation of Phagocytosis by Macrophages. J. Mater. Chem. B5 (32), 6666–6675. 10.1039/c7tb00648a

  • CrossRef
  • Google Scholar

• 107

  SiY.ChenK.NgoH. G.GuanJ. S.TotoroA.ZhouZ.et al (2022). Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers. Pharmaceutics14 (1). 146. 10.3390/pharmaceutics14010146

  • CrossRef
  • Google Scholar

• 108

  SicaA.SchioppaT.MantovaniA.AllavenaP. (2006). Tumour-associated Macrophages Are a Distinct M2 Polarised Population Promoting Tumour Progression: Potential Targets of Anti-cancer Therapy. Eur. J. Cancer42 (6), 717–727. 10.1016/j.ejca.2006.01.003

  • CrossRef
  • Google Scholar

• 109

  SikicB. I.LakhaniN.PatnaikA.ShahS. A.ChandanaS. R.RascoD. (2019). First-in-human, First-In-Class Phase I Trial of the Anti-cd47 Antibody Hu5f9-G4 in Patients with Advanced Cancers. J. Clin. Oncol.37 (12), 946–953. 10.1200/JCO.18.02018

  • CrossRef
  • Google Scholar

• 110

  SongS.JinX.ZhangL.ZhaoC.DingY.AngQ.et al (2019). PEGylated and CD47-Conjugated Nanoellipsoidal Artificial Antigen-Presenting Cells Minimize Phagocytosis and Augment Anti-tumor T-Cell Responses. Int. J. Nanomedicine14, 2465–2483. 10.2147/IJN.S195828

  • CrossRef
  • Google Scholar

• 111

  SunX.HongY.GongY.ZhengS.XieD. (2021). Bioengineered Ferritin Nanocarriers for Cancer Therapy. Int. J. Mol. Sci.22 (13). 1. 10.3390/ijms22137023

  • CrossRef
  • Google Scholar

• 112

  TangY.TangZ.LiP.TangK.MaZ.WangY.et al (2021). Precise Delivery of Nanomedicines to M2 Macrophages by Combining "Eat Me/Don't Eat Me" Signals and its Anticancer Application. ACS Nano15 (11), 18100–18112. 10.1021/acsnano.1c06707

  • CrossRef
  • Google Scholar

• 113

  TawfikS. M.AzizovS.ElmasryM. R.SharipovM.LeeY. I. (2020). Recent Advances in Nanomicelles Delivery Systems. Nanomaterials (Basel)11 (1). 10.3390/nano11010070

  • CrossRef
  • Google Scholar

• 114

  TorchilinV. P. (2007). Micellar Nanocarriers: Pharmaceutical Perspectives. Pharm. Res.24 (1), 1–16. 10.1007/s11095-006-9132-0

  • CrossRef
  • Google Scholar

• 115

  VoetsE.ParadeM.Lutje HulsikD.SpijkersS.JanssenW.RensJ.et al (2019). Functional Characterization of the Selective Pan-Allele Anti-SIRPalpha Antibody ADU-1805 that Blocks the SIRPalpha-CD47 Innate Immune Checkpoint. J. Immunother. Cancer7 (1), 340. 10.1186/s40425-019-0772-0

  • CrossRef
  • Google Scholar

• 116

  WangM.ZurisJ. A.MengF.ReesH.SunS.DengP.et al (2016). Efficient Delivery of Genome-Editing Proteins Using Bioreducible Lipid Nanoparticles. Proc. Natl. Acad. Sci. U S A.113 (11), 2868–2873. 10.1073/pnas.1520244113

  • CrossRef
  • Google Scholar

• 117

  WangY.NiH.ZhouS.HeK.GaoY.WuW.et al (2021). Tumor-selective Blockade of CD47 Signaling with a CD47/PD-L1 Bispecific Antibody for Enhanced Anti-tumor Activity and Limited Toxicity. Cancer Immunol. Immunother.70 (2), 365–376. 10.1007/s00262-020-02679-5

  • CrossRef
  • Google Scholar

• 118

  WangY.WangZ.QianY.FanL.YueC.JiaF.et al (2019). Synergetic Estrogen Receptor-Targeting Liposome Nanocarriers with Anti-phagocytic Properties for Enhanced Tumor Theranostics. J. Mater. Chem. B7 (7), 1056–1063. 10.1039/c8tb03351j

  • CrossRef
  • Google Scholar

• 119

  WangY.ZhaoQ.HanN.BaiL.LiJ.LiuJ.et al (2015). Mesoporous Silica Nanoparticles in Drug Delivery and Biomedical Applications. Nanomedicine11 (2), 313–327. 10.1016/j.nano.2014.09.014

  • CrossRef
  • Google Scholar

• 120

  WillinghamS. B.VolkmerJ.-P.GentlesA. J.SahooD.DalerbaP.MitraS. S.et al (2012). The CD47-Signal Regulatory Protein Alpha (SIRPa) Interaction Is a Therapeutic Target for Human Solid Tumors. Proc. Natl. Acad. Sci. U.S.A.109 (17), 6662–6667. 10.1073/pnas.1121623109

  • CrossRef
  • Google Scholar

• 121

  WuC. C.YangY. C.HsuY. T.WuT. C.HungC. F.HuangJ. T. (2015). Nanoparticle-induced Intraperitoneal Hyperthermia and Targeted Photoablation in Treating Ovarian Cancer. Oncotarget6 (29), 26861–26875. 10.18632/oncotarget.4766

  • CrossRef
  • Google Scholar

• 122

  WuK.SuD.LiuJ.SahaR.WangJ. P. (2019). Magnetic Nanoparticles in Nanomedicine: a Review of Recent Advances. Nanotechnology30 (50), 502003. 10.1088/1361-6528/ab4241

  • CrossRef
  • Google Scholar

• 123

  WuM. X.YangY. W. (2017). Metal-Organic Framework (MOF)-Based Drug/Cargo Delivery and Cancer Therapy. Adv. Mater.29 (23). 1. 10.1002/adma.201606134

  • CrossRef
  • Google Scholar

• 124

  WuW.LuoL.WangY.WuQ.DaiH. B.LiJ. S.et al (2018). Endogenous pH-Responsive Nanoparticles with Programmable Size Changes for Targeted Tumor Therapy and Imaging Applications. Theranostics8 (11), 3038–3058. 10.7150/thno.23459

  • CrossRef
  • Google Scholar

• 125

  XiaY.RaoL.YaoH.WangZ.NingP.ChenX. (2020). Engineering Macrophages for Cancer Immunotherapy and Drug Delivery. Adv. Mater.32 (40). 1. 10.1002/adma.202002054

  • CrossRef
  • Google Scholar

• 126

  XieX.LianS.ZhouY.LiB.LuY.YeungI.et al (2021). Tumor-derived Exosomes Can Specifically Prevent Cancer Metastatic Organotropism. J. Control. Release331, 404–415. 10.1016/j.jconrel.2021.01.030

  • CrossRef
  • Google Scholar

• 127

  XieZ.PengM.LuR.MengX.LiangW.LiZ.et al (2020). Black Phosphorus-Based Photothermal Therapy with aCD47-Mediated Immune Checkpoint Blockade for Enhanced Cancer Immunotherapy. Light Sci. Appl.9, 161. 10.1038/s41377-020-00388-3

  • CrossRef
  • Google Scholar

• 128

  XingQ.PanY.HuY.WangL. (2020). Review of the Biomolecular Modification of the Metal-Organ-Framework. Front. Chem.8. 642. 10.3389/fchem.2020.00642

  • CrossRef
  • Google Scholar

• 129

  XuX.HoW.ZhangX.BertrandN.FarokhzadO. (2015). Cancer Nanomedicine: from Targeted Delivery to Combination Therapy. Trends Mol. Med.21 (4), 223–232. 10.1016/j.molmed.2015.01.001

  • CrossRef
  • Google Scholar

• 130

  YanagitaT.MurataY.TanakaD.MotegiS.-i.AraiE.DaniwijayaE. W.et al (2017). Anti-Sirpα Antibodies as a Potential New Tool for Cancer Immunotherapy. JCI Insight2 (1), e89140. 10.1172/jci.insight.89140

  • CrossRef
  • Google Scholar

• 131

  YangB.SongB. P.ShankarS.GullerA.DengW. (2021). Recent Advances in Liposome Formulations for Breast Cancer Therapeutics. Cell Mol Life Sci78 (13), 5225–5243. 10.1007/s00018-021-03850-6

  • CrossRef
  • Google Scholar

• 132

  YuY. L.ChouR. H.LiangJ. H.ChangW. J.SuK. J.TsengY. J.et al (2013). Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides. PLoS One8 (4), e61362. 10.1371/journal.pone.0061362

  • CrossRef
  • Google Scholar

• 133

  ZhanX.TengW.SunK.HeJ.YangJ.TianJ.et al (2021). CD47-mediated DTIC-Loaded Chitosan Oligosaccharide-Grafted nGO for Synergistic Chemo-Photothermal Therapy against Malignant Melanoma. Mater. Sci. Eng. C Mater. Biol. Appl.123, 112014. 10.1016/j.msec.2021.112014

  • CrossRef
  • Google Scholar

• 134

  ZhangF.ZhangY.KongL.LuoH.ZhangY.MakilaE.et al (2021). Multistage Signal-Interactive Nanoparticles Improve Tumor Targeting through Efficient Nanoparticle-Cell Communications. Cell Rep35 (8), 109131. 10.1016/j.celrep.2021.109131

  • CrossRef
  • Google Scholar

• 135

  ZhangW.HuangQ.XiaoW.ZhaoY.PiJ.XuH.et al (2020). Advances in Anti-tumor Treatments Targeting the CD47/SIRPalpha Axis. Front. Immunol.11, 18. 10.3389/fimmu.2020.00018

  • CrossRef
  • Google Scholar

• 136

  ZhaoW.HuX.LiW.LiR.ChenJ.ZhouL.et al (2021). M2-Like TAMs Function Reversal Contributes to Breast Cancer Eradication by Combination Dual Immune Checkpoint Blockade and Photothermal Therapy. Small17 (13), e2007051. 10.1002/smll.202007051

  • CrossRef
  • Google Scholar

• 137

  ZhengH.ZhangY.LiuL.WanW.GuoP.NystromA. M.et al (2016). One-pot Synthesis of Metal-Organic Frameworks with Encapsulated Target Molecules and Their Applications for Controlled Drug Delivery. J. Am. Chem. Soc.138 (3), 962–968. 10.1021/jacs.5b11720

  • CrossRef
  • Google Scholar

• 138

  ZhuY.SundaramH. S.LiuS.ZhangL.XuX.YuQ.et al (2014). A Robust Graft-To Strategy to Form Multifunctional and Stealth Zwitterionic Polymer-Coated Mesoporous Silica Nanoparticles. Biomacromolecules15 (5), 1845–1851. 10.1021/bm500209a

  • CrossRef
  • Google Scholar

• 139

  ZitvogelL.ApetohL.GhiringhelliF.KroemerG. (2008). Immunological Aspects of Cancer Chemotherapy. Nat. Rev. Immunol.8 (1), 59–73. 10.1038/nri2216

  • CrossRef
  • Google Scholar